Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to ...
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved ...
Regeneron, Sanofi announce presentation of Dupixent Phase 3 data in CSU
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will present data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use ...
Finanznachrichten16h
Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end; if ...
Managed Healthcare Executive3d
Long-Term Dupixent Treatment Shows Promising Results for Severe Atopic Dermatitis
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Morningstar3d
Regeneron's Eye Disease Drug Eylea and Immunology Drug Dupixent Support a Narrow Moat
Immunology drug Dupixent is seeing very strong, steady growth in atopic dermatitis and asthma, and approvals continue to expend to new indications (nasal polyposis) and younger patients.
Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
Madrigal faces financial challenges and competition for Rezdiffra. Read more to understand why MDGL stock is downgraded from ...
Sanofi Expected to Report Higher Sales; Capital Allocation in Focus -- Earnings Preview
SALES FORECAST: The Paris-based group's sales are forecast at 12.63 billion euros, according to Visible Alpha. That compares with 11.96 billion euros for the same period the year before. As of ...
2minutemedicine.com2d
Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients
Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...
Diana Taurasi still mulling over decision to retire or play another year
Diana Taurasi is still mulling over her decision whether to play another season in the WNBA or retire. The 20-year veteran ...
pharmaphorum5d
Dupixent delivers in two skin disease trials
Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...